New Mass Spectrometry Portfolio Leverages Enhanced Hardware and Software to Advance Quantitative Analysis

New Mass Spectrometry Portfolio: Lab managers, technology leaders and principal scientists in pharmaceutical, food and environmental laboratories can now benefit from accelerated throughput and improved sensitivity to meet rapidly changing regulatory requirements and provide the fast responses needed for tackling emerging human and environmental health risks.

The Thermo Scientific TSQ Plus triple quadrupole mass spectrometer (MS) portfolio increases workflow throughput through superior data acquisition and polarity switching speeds. The improved low-mass product ion transmission efficiency enhances sensitivity for key target applications. The new portfolio, which consists of the TSQ Altis Plus, TSQ Quantis Plus and TSQ Fortis Plus MS, can be used across a range of applications, from targeted quantitation to cutting-edge research. Intuitive mass calibration routines and method optimization, in combination with market-leading chromatography and data processing software solutions, offers improved ease of use to address future analytical challenges.

“Laboratories performing routine quantitative experiments continue to need to identify new compounds of interest across industries, such as pharma, food and environmental, resulting in rapidly changing regulations and lower detection limits,” said August Specht, vice president, research and development, chromatography and mass spectrometry, Thermo Fisher. “In order to protect consumer and environmental health, laboratories need to provide comprehensive workflows to address evolving requirements, and the TSQ Plus triple quadrupole MS portfolio has been designed to deliver.”

Professor Julijana Ivanisevic, University of Lausanne, said “The TSQ Altis Plus platform is a step forward toward omics-scale, quantitative MS-based methodology for in-depth investigation of metabolism. The unprecedented acquisition speed of the TSQ Altis Plus allows us to maximize the metabolome coverage and significantly enhances the peak definition, essential for accurate quantification. The TSQ Altis Plus mass spectrometer allows for robust quantification of low abundant species, thus complementing the comprehensiveness of measured metabolite signature. This increase in productivity, along with the quantitative aspect, is crucial for metabolic phenotyping of human populations – a prerequisite for the transfer to clinical settings.”

Users of the TSQ Plus triple quadrupole MS portfolio will benefit from:

  • Increased system uptime due to enhanced quadrupole mass stability.
  • Direct instrument method transfers from the existing Thermo Scientific TSQ MS portfolio to the TSQ Plus MS portfolio, enabling simplified transfers.
  • Integration with mzCloud database to provide Selective Reaction Monitoring (SRM) transition information with predicted collision energy.
  • Integration with industry-leading liquid- and ion-chromatography systems and software, delivering powerful quantitative application solutions.
  • Other news from the company today here.
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy